Q1 2022 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Reduced by SVB Leerink

Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) – Equities researchers at SVB Leerink lowered their Q1 2022 EPS estimates for Neurocrine Biosciences in a research note issued to investors on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the company will earn $0.25 per share for the quarter, down from their prior estimate of $0.26. SVB Leerink also issued estimates for Neurocrine Biosciences’ Q2 2022 earnings at $0.31 EPS, Q3 2022 earnings at $0.62 EPS and Q4 2022 earnings at $0.58 EPS.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last issued its earnings results on Friday, February 11th. The company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of $0.61 by ($0.69). Neurocrine Biosciences had a return on equity of 6.89% and a net margin of 7.90%. The company had revenue of $312.00 million during the quarter, compared to the consensus estimate of $317.72 million. During the same quarter in the prior year, the company earned $3.58 earnings per share. Neurocrine Biosciences’s revenue was up 25.9% on a year-over-year basis.

A number of other equities analysts also recently issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Neurocrine Biosciences from $125.00 to $126.00 and gave the company an “overweight” rating in a research note on Monday, April 4th. StockNews.com upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Monday, March 28th. Jefferies Financial Group downgraded shares of Neurocrine Biosciences to a “hold” rating and set a $94.00 price objective on the stock. in a research note on Thursday, March 3rd. Barclays increased their price objective on shares of Neurocrine Biosciences from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, April 12th. Finally, Morgan Stanley increased their target price on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the company an “equal weight” rating in a research report on Monday, February 14th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $111.17.

NASDAQ NBIX opened at $95.76 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.83 and a current ratio of 3.96. The firm’s 50 day moving average price is $92.49 and its 200-day moving average price is $89.16. Neurocrine Biosciences has a 52-week low of $71.88 and a 52-week high of $108.01. The company has a market cap of $9.15 billion, a PE ratio of 105.23, a P/E/G ratio of 4.74 and a beta of 0.71.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Whittier Trust Co. grew its holdings in Neurocrine Biosciences by 102.8% during the 4th quarter. Whittier Trust Co. now owns 290 shares of the company’s stock worth $25,000 after acquiring an additional 147 shares in the last quarter. KB Financial Partners LLC purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at $33,000. Orion Capital Management LLC purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at $34,000. CI Investments Inc. purchased a new stake in Neurocrine Biosciences in the 3rd quarter valued at $39,000. Finally, Meeder Asset Management Inc. raised its position in Neurocrine Biosciences by 460.0% in the 3rd quarter. Meeder Asset Management Inc. now owns 504 shares of the company’s stock valued at $48,000 after purchasing an additional 414 shares during the last quarter. Institutional investors own 95.93% of the company’s stock.

In other Neurocrine Biosciences news, Director William H. Rastetter sold 10,728 shares of Neurocrine Biosciences stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $94.93, for a total transaction of $1,018,409.04. Following the transaction, the director now directly owns 34,022 shares of the company’s stock, valued at $3,229,708.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Darin Lippoldt sold 300 shares of Neurocrine Biosciences stock in a transaction dated Friday, March 18th. The stock was sold at an average price of $95.00, for a total transaction of $28,500.00. The disclosure for this sale can be found here. Insiders have sold 46,743 shares of company stock worth $3,957,821 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

About Neurocrine Biosciences (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

See Also

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.